Back to search

Ireland· IE-PA-EU/1/18/1308/001-003

Vyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusion

A cytarabine and daunorubicin product containing cytarabine + daunomycin hydrochloride, registered in Ireland by Jazz Pharmaceuticals Ireland Limited. The same ATC class is registered in 13 of our 19 countries.

ATC L01XY01

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedVyxeos liposomal 44 mg/100 mg powder …ATCL01XY01REGISTER NO.IE-PA-EU/1/18/1308/00…PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Cytarabine and daunorubicin is registered in 13 of 19 countries.

Countries holding a registration under ATC L01XY01 (cytarabine and daunorubicin), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 8 of them publish a price we can compare per daily dose

Cytarabine and daunorubicin · ATC L01XY01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Cytarabine + DAUNOMYCIN HYDROCHLORIDE
Manufacturer
Jazz Pharmaceuticals Ireland Limited
Country
Ireland (IE)
ATC code
L01XY01
ATC class
Cytarabine and daunorubicin
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/18/1308/001-003

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8b4a4f08-9c7d-4145-9e26-76461109d68e
GET /v1/drugs/8b4a4f08-9c7d-4145-9e26-76461109d68e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for concentrate for solution for infusion",
  "routes": [
    "Intravenous use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XY01"
  ],
  "strength": null,
  "pa_number": "EU/1/18/1308/001-003",
  "substances": [
    "Cytarabine",
    "DAUNOMYCIN HYDROCHLORIDE"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "23/08/2018",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about cytarabine and daunorubicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.